swissfillon AG

JERSEY CITY, N.J., Oct. 25, 2023 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on "Global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Size, Share & Trends Analysis Report By Type of Container (Sterile Cartridges, Sterile Syringes, and Sterile Vials), Type of Closure (Caps, Plungers, Seals, Stoppers, Tip Caps / Needle Shields), Material of Fabrication (Aluminum, Glass, Plastic, and Rubber)-Market Outlook And Industry Analysis 2031." Continue Reading InsightAce Analytic Pvt. Ltd According to the latest research by InsightAce Analytic, the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market size is valued at US$ 8.42 Bn in 2022, and it is expected to reach US$ 14.23 Bn in 2031, recording a promising CAGR of 6.13% during the forecast period of 2023-2031. The primary packaging of drugs and vaccines is important in ensuring their integrity, quality and protecting them from contaminants. Hence, sterilization is essential in pharmaceutical manufacturing because it helps maintain product safety and adhere to strict quality standards. This has increased the importance of pre-sterilized/ready-to-use containers in pharmaceutical packaging. Ready-to-use vials eliminate the need for in-house sterilization processes, reducing contamination risks and production timelines. The surging demand for safe drug delivery systems has enhanced the growth of the Pre-Sterilized/Ready to Use Pharmaceutical packaging market. Recent advances in packaging materials and technologies have resulted in innovative solutions offering high drug compatibility, stability, and barrier properties. The advantages offered by empty sterile vials and syringes, and their increasing demand in the healthcare sector, specifically after the COVID-19 pandemic, have prompted manufacturers to implement advancements that are likely to propel the market growth during the forecast period. Request for Sample Pages: Some of the prominent players in the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market are: ABB Afton Scientific ALK Life Science Solutions Allergy Laboratories AptarGroup Aseptic Technologies Becton Dickinson Berkshire Sterile Manufacturing Bharat Rubber Works BioPharma Solutions Bormioli Pharma Catalent Centor COLANAR Corning Credence MedSystems Daikyo Seiko Dara Pharmaceutical Packaging Datwyler Group DENSO Disposable-Lab (Acquired by Amatsigroup) DWK Life Sciences EMA Pharmaceuticals Amatsigroup (Acquired by Eurofins CDMO) FANUC America GCL Pharma (Acquired by Bormioli Pharma) Gerresheimer Huayi Isotopes Company IMA ISOLAB Jiangsu Hualan New Pharmaceutical Material Kawasaki Heavy Industries Klenzaids Contamination Controls KUKA Marchesini Group MedCision MedicoPack Merck Momentive Technologies Muller + Muller (Acquired by DWK Life Sciences) Nelson Labs Nemera Ningbo Zhengli Pharmaceutical Packaging Nipro OMRON Industrial Automation Origin Pharma Packaging Ott (Acquired by Datwyler Group) Pall Pfeiffer Vacuum Pfizer Philabundance Prince Sterilization Services Qingdao Huaren Medical Product Radpharm Scientific Retractable Technologies Sagar Rubber Samsung Medical Rubber Sartorius SCHOTT Seiko Epson SGD Pharma SiO2 Materials Science Sonata Rubber Staubli Steriline Sterisets International Stevanato Group SureCare SVM Automatik Swissfillon Syntegon Tekpak Terumo Toxikon Europe (Acquired by Sterigenics International) Transcoject Triveni Polymers (Acquired by Gerresheimer) Universal Medicap Universal Robots United Pharmacy Partners (UPPI) Vaccines Manufacturing and Innovation Centre Vanrx Pharmasystems Vetter Pharma VIGHNESH Rubbers Watson-Marlow Fluid Technology Group West Pharmaceutical Services YangZhong Wealth Metal Yaskawa Electric Ypsomed Curious about this latest version of the report? Enquiry Before Buying: Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Report Scope Market Dynamics: Drivers: The main factors responsible for driving the Pre-Sterilized/Ready to Use Pharmaceutical packaging market are increasing preference towards patient safety and rising importance for sterility and integrity of pharmaceutical products. In addition, strict regulatory guidelines set by regulatory agencies such as the FDA and EMA play an essential role in booming the demand for pre-sterilized pharmaceutical packaging. Moreover, the complex manufacturing of advanced therapies such as cell and gene therapies led to a surge in the need for suitable containers for ATMP aseptic filling & finishing. The addition of RTU (ready-to-use) packaging into the pharmaceutical industry ensures that the product is quickly available through the optimized supply chain. Further, the high demand for COVID-19 vaccines has boosted market growth, especially for sterile vials. Regional Trends: North America captured the highest revenue share of the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market in 2022 and is expected to continue its growth during the forecast period 2023-2031. This growth can be attributed to the increasing demand for pharmaceutical products, well-developed healthcare infrastructure, and rising government efforts and investments in developing pharmaceutical facilities. Besides, the Asia Pacific region is anticipated to grow faster in the next few years. Key developments in the market: In June 2022, Schott invested multi-Bn euros to increase sterile RTU vials production at its facility in Pennsylvania, US. In March 2022, Stevanato expanded its vial manufacturing operations to meet the need for vaccines during the pandemic under a contract with the Biomedical Advanced Research and Development Authority (BARDA). The company has invested in expanding the production capacity for both standard RTU vials and EZ fill RTU vials. In March 2022, SGD Pharma introduced a 100 ml ready-to-use sterile glass vial, catering to the demand for small and large sterile vials. Market Segments Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Container Sterile Cartridges Sterile Syringes Sterile Vials Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Closure Caps Plungers Seals Stoppers Tip Caps / Needle Shields Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Material of Fabrication Aluminum Glass Rubber Plastic Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Region North America Europe Asia Pacific Latin America Middle East & Africa North America Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 U.S. Canada Europe Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 Germany France Italy Spain Russia Rest of Europe Asia Pacific Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 India China Japan South Korea Australia & New Zealand Latin America Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 Brazil Mexico Rest of Latin America Middle East & Africa Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Revenue (US$ Bn) by Country, 2023 to 2031 GCC Countries South Africa Rest of Middle East & Africa Obtain Report Customization Details @ Why should buy this report: To receive a comprehensive analysis of the prospects for the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market To receive an industry overview and future trends in the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market To analyze the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market drivers and challenges To get information on the Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market size value (US$ Mn) forecast till 2031 Major Investments, Mergers & Acquisitions in the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market industry Other Related Reports Published by InsightAce Analytic: Pharmaceutical Packaging Market Research Report 2023 Sustainable Pharmaceutical Packaging Market Research Report 2023 Pharmaceutical Plastic Bottles Market Research Report 2023 About Us: InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner. Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 551 226 6109 Email: [email protected] Site Visit: Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ Logo - SOURCE InsightAce Analytic Pvt. Ltd

- Establishes Fiscal 2023 Guidance - PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2022, and established fiscal 2023 guidance. Fourth Quarter and Full Year 2022 Highlights (compared with the same periods last year) Fourth quarter revenue increased 26% to €292.1 million, diluted EPS were €0.18, and adjusted diluted EPS were €0.19. Adjusted EBITDA margin was 28%. Fiscal year 2022 revenue grew 17% to €983.7 million, diluted EPS were €0.54, and adjusted diluted EPS were €0.56. Adjusted EBITDA margin was 26.8%. Revenue from high value solutions was approximately 30% of total revenue for both the fourth quarter and the full year. Committed backlog increased 9% to approximately €957 million and, excluding Covid-19, increased 21%. The Company is establishing full year 2023 guidance of revenue in the range of €1.085 billion to €1.115 billion, adjusted diluted EPS between €0.58 and €0.62, and adjusted EBITDA in the range of €290.5 million to €302.5 million. Fourth Quarter Results Revenue for the fourth quarter of 2022 increased 26% to €292.1 million (approximately 23% on a constant currency basis), compared with the same period last year, driven by growth in both of the Company's business segments, the shift to high value solutions, and favorable foreign currency translation. Top-line results for the fourth quarter were better than expected due to the timing of revenue that was previously forecasted in Q1 2023. This includes revenue from certain Engineering projects and Covid-19. As a result, revenue from Covid-19 represented approximately 12% of total revenue. As expected, revenue from high value solutions increased to 30% of total revenue for the fourth quarter. For the fourth quarter of 2022, gross profit margin increased 290 basis points to 34.3% driven by higher revenue, the mix shift to high value solutions, better leverage of fixed costs, and the recovery of inflationary costs, while operating profit margin of 21.6% included a benefit of €3.0 million related to a joint development project. Full Year 2022 Results Revenue for fiscal 2022 increased 17% to €983.7 million (approximately 13% on a constant currency basis), compared with the same period last year, driven by growth in both of the Company's business segments, the shift to high value solutions and favorable foreign currency translation. As expected, full-year revenue growth was partially offset by lower revenue from Covid-19, which accounted for 11% of revenue. Revenue from high value solutions was approximately 30% of full-year revenue, compared to 25% in 2021. For the full year 2022, strong revenue generation, favorable mix, and operating efficiencies led to a 110 basis point increase in gross profit margin of 32.5%, which was tempered by inflation. Operating profit margin improved to 19.6% for 2022. Franco Moro, Chief Executive Officer, stated, “We are pleased with a strong finish to 2022, thanks to the collective efforts of our employees worldwide. Over the last 18 months, we have worked alongside customers to address their growing need for high value solutions. With this added visibility, future capacity demand in the United States and Europe has outpaced our initial expectations. As a result, we are accelerating investment in the United States to meet our customers' most pressing needs and capitalize on this favorable demand. Concurrently, we are slowing the timing of our project in China to prioritize our expansion efforts in the U.S. and Italy." Biopharmaceutical and Diagnostic Solutions Segment (BDS) Revenue grew 25% to €231.5 million (approximately 21% on a constant currency basis), for the fourth quarter of 2022 and 15% to €799.7 million (approximately 11% on a constant currency basis) for the full year, compared with the same periods last year. Period-to-period increases were driven by growth in core drug containment products. For the fourth quarter of 2022, revenue from high value solutions increased to €87.2 million, while revenue from other containment and delivery solutions increased to €144.3 million. For the full year, revenue from high value solutions increased 41% to €293.2 million, while revenue from other containment and delivery solutions grew 4% to €506.4 million. Year-over-year gross profit margin expansion in the fourth quarter was driven by higher revenue, mix, better leverage from fixed costs and the recovery of inflationary costs. For the full year, the Company's growth, favorable mix shift, and operating efficiencies helped expand gross profit margin, which was also tempered by inflation. Operating profit margin in both the quarter and the fiscal year benefited from increases in other income. Engineering Segment Revenue increased 30% to €60.6 million for the fourth quarter of 2022 and was slightly ahead of expectations due to the timing and progression of projects. For the full year, revenue grew 23% to €184.0 million, compared with the same periods last year. For the fourth quarter of 2022, gross profit margin and operating profit margin decreased compared with the same period last year mostly due to project mix, but on a full-year basis both gross profit margin and operating profit margin improved mainly driven by contributions from more accretive business lines and ongoing optimization efforts to improve operational efficiencies. Balance Sheet and Cash Flow As of December 31, 2022, the Company had net cash of €46.0 million and cash and cash equivalents of €228.7 million. As expected, capital expenditures for the full year totaled €302.6 million, as the Company continued its investment in global expansion initiatives. For fiscal year 2022, cash generated from operating activities was €103.3 million, reflecting increased working capital needs to fund growth initiatives and higher levels of inventory to mitigate supply chain risk in the current environment. As expected, cash used for investing activities was €243.0 million and the main contributor to negative free cash flow of €137.0 million. New Order Intake and Backlog For the fourth quarter of 2022, new order intake totaled approximately €237 million, compared with €278 million in the same period last year. The Company ended the year with a committed backlog of approximately €957 million, a 9% increase over the same period last year, reflecting the expected decline in orders related to Covid-19. Excluding Covid-19, backlog increased 21%. Full Year 2023 Guidance The Company is introducing fiscal year 2023 guidance and expects: Revenue in the range of €1.085 billion to €1.115 billion, Adjusted diluted EPS in the range of €0.58 to €0.62, Adjusted EBITDA in the range of €290.5 million to €302.5 million. In addition, the Company expects that capital expenditures will range between 35% and 40% of revenue. Executive Chairman, Franco Stevanato, concluded, "With yet another year of consistent delivery against our financial objectives amid a favorable demand environment, we are well positioned to capitalize on increased customer demand and secular tailwinds to drive durable organic growth to create long-term shareholder value." Conference Call The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 2, 2023 to discuss financial results. During the call, management will refer to a slide presentation which will be available at 6:30 a.m. (ET) on the day of the call on the “Financial Results” page under the Company's Investor Relations section of its website. Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the call using the following link: Webcast: A live, listen-only webcast of the call will be available at the following link: Dial in: Those who are unable to pre-register may dial in by calling: Italy: + 39 02 802 09 11 UK: + 44 1 212 818004 USA: +1 718 705 8796 USA Toll Free: +1 855 265 6958 Replay: The webcast will be archived for three months on the Company’s Investor Relations section of its website at: Forward-Looking Statements This press release may include forward-looking statements. The words "expects,” “establishing,” “future,” “accelerating,” “slowing,” “committed,” “expected,” “introducing,” “visibility,” “increased,” “well positioned,” “drive,” “create,” “growing,” “favorable,” and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the U.S., its capital expenditure guidance, business strategies, the Company’s capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. For a description of the risks that could cause the Company’s future results to differ from those expressed in any such forward looking statements, refer to the risk factors discussed in our most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements. Non-GAAP Financial Information This press release contains non-GAAP financial measures. Please refer to the tables included in this press release for a reconciliation of non-GAAP financial measures. Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Net Profit, Adjusted Diluted EPS, Capital Employed, Net Cash, Free Cash Flow, and CAPEX. We believe that these non-GAAP financial measures provide useful and relevant information regarding our performance and improve our ability to assess our financial condition. While similar measures are widely used in the industry in which we operate, the financial measures we use may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS. About Stevanato Group Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: . Consolidated Income Statement (Amounts in € millions, except per share data) (Unaudited) For the three months For the years ended December 31, ended December 31, 2022 % 2021 % 2022 % 2021 % Revenue 292.1 100.0 % 232.6 100.0 % 983.7 100.0 % 843.9 100.0 % Costs of sales 191.9 65.7 % 159.6 68.6 % 663.9 67.5 % 578.5 68.6 % Gross Profit 100.2 34.3 % 73.0 31.4 % 319.8 32.5 % 265.4 31.4 % Other operating Income 6.7 2.3 % 2.2 0.9 % 18.8 1.9 % 9.4 1.1 % Selling and Marketing Expenses 8.3 2.8 % 4.4 1.9 % 26.1 2.7 % 20.4 2.4 % Research and Development Expenses 10.6 3.6 % 9.5 4.1 % 34.4 3.5 % 29.6 3.5 % General and Administrative Expenses 24.9 8.5 % 17.8 7.7 % 85.7 8.7 % 62.5 7.4 % Operating Profit 63.1 21.6 % 43.5 18.7 % 192.4 19.6 % 162.2 19.2 % Finance Income 7.8 2.7 % 15.3 6.6 % 25.0 2.5 % 21.7 2.6 % Finance Expense 7.1 2.4 % 5.1 2.2 % 29.8 3.0 % 18.8 2.2 % Share of Profit of an Associate — 0.0 % — 0.0 % — 0.0 % 0.5 0.1 % Profit Before Tax 63.8 21.9 % 53.7 23.1 % 187.6 19.1 % 165.7 19.6 % Income Taxes 15.5 5.3 % 9.1 3.9 % 44.6 4.5 % 31.4 3.7 % Net Profit 48.3 16.5 % 44.6 19.2 % 143.0 14.5 % 134.3 15.9 % Earnings per share Basic earnings per common share 0.18 0.17 0.54 0.53 Diluted earnings per common share 0.18 0.17 0.54 0.53 Average common shares outstanding 264.7 264.7 264.7 252.7 Average shares assuming dilution 264.7 264.7 264.7 252.7 Reported Segment Information (Amounts in € millions) (Unaudited) For the three months ended December 31, 2022 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 231.5 60.6 — 292.1 Inter-Segment 0.6 31.8 (32.4 ) — Revenue 232.1 92.4 (32.4 ) 292.1 Gross Profit 86.7 19.6 (6.1 ) 100.2 Gross Profit Margin 37.3 % 21.2 % 34.3 % Operating Profit 55.0 11.3 (3.2 ) 63.1 Operating Profit Margin 23.7 % 12.2 % 21.6 % For the three months ended December 31, 2021 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 185.9 46.7 — 232.6 Inter-Segment 0.3 29.7 (30.0 ) — Revenue 186.2 76.4 (30.0 ) 232.6 Gross Profit 61.1 16.6 (4.7 ) 73.0 Gross Profit Margin 32.8 % 21.7 % 31.4 % Operating Profit 37.9 10.9 (5.3 ) 43.5 Operating Profit Margin 20.3 % 14.3 % 18.7 % For the year ended December 31, 2022 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 799.7 184.0 — 983.7 Inter-Segment 1.5 115.5 (117.0 ) — Revenue 801.2 299.5 (117.0 ) 983.7 Gross Profit 274.9 64.7 (19.7 ) 319.8 Gross Profit Margin 34.3 % 21.6 % 32.5 % Operating Profit 182.6 41.3 (31.4 ) 192.4 Operating Profit Margin 22.8 % 13.8 % 19.6 % For the year ended December 31, 2021 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 694.0 149.9 — 843.9 Inter-Segment 1.1 69.0 (70.1 ) — Revenue 695.1 218.9 (70.1 ) 843.9 Gross Profit 229.9 42.2 (6.7 ) 265.4 Gross Profit Margin 33.1 % 19.3 % 31.4 % Operating Profit 149.0 22.9 (9.7 ) 162.2 Operating Profit Margin 21.4 % 10.5 % 19.2 % Cash Flow (Amounts in € millions) (Unaudited) For the three months ended December 31, For the years ended December 31, 2022 2021 2022 2021 Cash flow from operating activities 59.7 55.4 103.3 133.3 Cash flow used in investing activities (68.9 ) (21.1 ) (243.0 ) (96.4 ) Cash flow from/ (used in) financing activities (18.6 ) (52.4 ) (44.5 ) 254.8 Net change in cash and cash equivalents (27.8 ) (18.1 ) (184.2 ) 291.7 Non-U.S. GAAP Financial Information This press release contains non-U.S. GAAP financial measures. Please refer to "Non-U.S. GAAP Financial Information" and the tables included in this press release for a reconciliation of non-U.S. GAAP financial measures. Reconciliation of Revenue to Constant Currency Revenue (Amounts in € millions) (Unaudited) Three months ended December 31, 2022 Biopharmaceutical and Diagnostic Solutions Engineering Reported Revenue (IFRS GAAP) 231.5 60.6 Effect of changes in currency translation rates (7.1 ) 0.0 Organic Revenue (Non-IFRS GAAP) 224.4 60.6 Year ended December 31, 2022 Biopharmaceutical and Diagnostic Solutions Engineering Reported Revenue (IFRS GAAP) 799.7 184.0 Effect of changes in currency translation rates (27.0 ) 0.0 Organic Revenue (Non-IFRS GAAP) 772.7 184.0 Reconciliation of EBITDA (Amounts in € millions) (Unaudited) For the three months ended December 31, Change For the years ended December 31, Change 2022 2021 % 2022 2021 % Net Profit 48.3 44.6 8.3 % 143.0 134.3 6.5 % Income Taxes 15.5 9.1 70.3 % 44.6 31.4 42.1 % Finance Income (7.8 ) (15.3 ) (49.4 )% (25.0 ) (21.7 ) 15.4 % Finance Expenses 7.1 5.1 39.3 % 29.8 18.8 58.7 % Share of Profit of an Associate — — — (0.5 ) (100.0 )% Operating Profit 63.1 43.5 45.3 % 192.4 162.2 18.6 % Depreciation and Amortization 17.0 15.1 12.8 % 64.8 56.4 15.0 % EBITDA 80.2 58.6 36.9 % 257.3 218.6 17.7 % Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data) (Unaudited) Three months ended December 31, 2022 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 80.2 63.1 15.5 48.3 0.18 Adjusting items: Start-up costs new plants (1) 1.6 1.6 0.4 1.2 0.01 Restructuring and related charges (2) 0.1 0.1 — 0.1 0.00 Adjusted 81.9 64.8 15.9 49.6 0.19 Adjusted Margin 28.0 % 22.2 % — — — Three months ended December 31, 2021 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 58.6 43.5 9.1 44.6 0.17 Adjusting items: — — — — 0.00 IPO costs (3) 0.1 0.1 0.0 0.1 0.00 Out-of-cycle bonus to personnel (4) (0.2 ) (0.2 ) (0.0 ) (0.1 ) 0.00 Start-up costs U.S. plant (1) 0.4 0.4 0.1 0.3 0.00 Gain from the sale of an associate (6) — — — (12.3 ) (0.05 ) Patent Box (7) — — 0.5 (0.5 ) 0.00 Provision for tax audit on previous years (8) — — (0.9 ) 0.9 0.01 Adjusted 58.9 43.8 8.8 33.0 0.13 Adjusted Margin 25.3 % 18.8 % — — — Year ended December 31, 2022 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 257.3 192.4 44.6 143.0 0.54 Adjusting items: Start-up costs new plants (1) 6.2 6.2 1.6 4.6 0.02 Restructuring and related charges (2) 0.1 0.1 — 0.1 0.00 Adjusted 263.6 198.7 46.2 147.7 0.56 Adjusted Margin 26.8 % 20.2 % — — — Year ended December 31, 2021 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 218.6 162.2 31.4 134.3 0.53 Adjusting items: — — — — — IPO costs (3) 0.8 0.8 0.2 0.6 0.00 Out-of-cycle bonus to personnel (4) 6.5 6.5 1.8 4.8 0.02 Foreign exchange loss for derivative on IPO proceeds (5) — — 1.0 3.3 0.01 Start-up costs U.S. plant (1) 1.1 1.1 0.3 0.8 0.00 Gain from the sale of an associate (6) — — — (12.3 ) (0.05 ) Patent Box (7) — — 7.6 (7.6 ) (0.03 ) Provision for tax audit on previous years (8) — — (0.9 ) 0.9 0.01 Restructuring and related charges (2) 1.2 1.2 0.3 0.8 0.01 Incentive Plans Settlement (9) (9.9 ) (9.9 ) (4.8 ) (5.1 ) (0.02 ) Adjusted 218.3 161.9 36.9 120.5 0.48 Adjusted Margin 25.9 % 19.2 % — — — (1) During the three months and the year ended December 31, 2022, the Group recorded respectively €1.6 million and €6.2 million respectively, of start-up costs for the new plant in Fishers, Indiana, United States, in Zhangjiagang, China, and in Latina, Italy. During the three months and the year ended December 31, 2021, the Group recorded respectively €0.4 million and €1.1 million of start-up costs to further the construction of the new plant in Fishers, Indiana, United States. (2) During the three months and the year ended December 31, 2022, the Group recorded €0.1 million in restructuring and related charges for the merger of Innoscan A/S into SVM Automatik A/S. During the year ended December 31, 2021, the Group recorded €1.2 million in restructuring and related charges for the consolidation of Balda plants in the U.S. (3) During the three months and the year ended December 31, 2021, the Group recorded €0.1 million and €0.8 million, respectively, in general and administrative expenses, relating to the listing of Stevanato Group S.p.A. ordinary shares on the NYSE. (4) During the year ended December 31, 2021, the Group granted a €6.5 million discretionary, out-of-cycle bonus to employees. During the three months ended December 31, 2021, the Group recorded €(0.2) million, of general and administrative expenses, mainly due to exchange rate impact and an adjustment of the estimation made as of September 30, 2021. No such bonuses were awarded or disbursed for the year ended December 31, 2022. (5) During the year ended December 31, 2021, the Group recorded €4.3 million, as foreign exchange loss for derivative on IPO proceeds. (6) During the three months and the year ended December 31, 2021 the Group recorded €12.3 million from the sale of a minority interest in the associate Swissfillon AG. (7) During the year ended December 31, 2021, the Group reached an agreement with the Italian Tax Agency regarding the so-called “Patent box regime”, resulting in a retroactive €7.6 million tax saving for the financial years 2016-2020. The tax benefit was accounted for as €7.1 million for the nine months ended September 30, 2021, based on our estimates. We accounted for a total accrual of €0.5 million for the three months ended December 31, 2021. (8) During the three months and the year ended December 31, 2021, the Group accrued €0.9 million related to a tax audit on fiscal year 2016. (9) During the year ended December 31, 2021, the Group recorded €9.9 million, in general and administrative expenses, as accrual reversal related to the early termination of incentive plans aimed at a limited number of key managers. Capital Employed (Amounts in € millions) (Unaudited) As of December 31, 2022 As of December 31, 2021 - Goodwill and Other intangible assets 79.4 79.2 - Right of Use assets 19.3 22.7 - Property, plant and equipment 641.4 392.7 - Financial assets - investments FVTPL 0.8 1.1 - Other non-current financial assets 1.0 1.3 - Deferred tax assets 69.2 55.9 Non-current assets 811.1 552.9 - Inventories 213.3 148.9 - Contract Assets 103.4 62.1 - Trade receivables 212.7 165.3 - Trade payables (239.2 ) (164.8 ) - Advances from customers (26.6 ) (23.6 ) - Contract Liabilities (14.8 ) (18.8 ) Trade working capital 248.8 169.1 - Tax receivables and Other receivables 54.0 51.4 - Tax payables and Other liabilities (111.1 ) (85.3 ) Net working capital 191.7 135.3 - Deferred tax liabilities (21.0 ) (19.1 ) - Employees benefits (8.3 ) (11.9 ) - Provisions (5.5 ) (3.5 ) - Other non-current liabilities (18.1 ) (1.8 ) Total non-current liabilities and provisions (52.9 ) (36.3 ) Capital employed 949.9 651.9 Net cash/ (debt) 46.0 189.8 Equity (995.9 ) (841.7 ) Total equity and net debt (949.9 ) (651.9 ) Free Cash Flow (Amounts in € millions) (Unaudited) For the three months ended December 31, For the years ended December 31, 2022 2021 2022 2021 Cash Flow from Operating Activities 59.7 55.4 103.3 133.3 Interest paid 1.0 1.3 3.5 4.4 Interest received (0.3 ) (0.2 ) (0.8 ) (0.6 ) Purchase of property, plant and equipment (67.9 ) (36.3 ) (235.0 ) (107.7 ) Proceeds from sale of property, plant and equipment (0.4 ) 1.2 0.1 1.2 Purchase of intangible assets (0.3 ) (2.1 ) (8.1 ) (5.5 ) Free Cash Flow (8.2 ) 19.3 (137.0 ) 25.1 Net Cash (Amounts in € millions) (Unaudited) As of December 31, As of December 31, 2022 2021 Non-current financial liabilities (148.4 ) (202.3 ) Current financial liabilities (70.7 ) (46.2 ) Other non-current financial assets - Derivatives 2.8 — Other current financial assets 33.6 27.2 Cash and cash equivalents 228.7 411.0 Net Cash/ (Debt) 46.0 189.8 CAPEX (Amounts in € millions) For the year ended December 31, Change 2022 2021 € Addition to Property, plants and equipment 294.5 116.6 177.9 Addition to Intangible Assets 8.1 5.5 2.6 CAPEX 302.6 122.1 180.5 Reconciliation of 2023 Guidance Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data) (Unaudited) Revenue EBITDA Operating Profit Net Profit Diluted EPS Reported 1,085.0 - 1,115.0 281.3 - 293.3 199.9 - 211.9 147.8 - 156.9 0.56 - 0.59 Adjusting items: Start-up costs new plants 9.1 9.1 6.8 0.03 Adjusted 1,085.0 - 1,115.0 290.5 - 302.5 209.0 - 221.0 154.6 - 163.7 0.58 - 0.62

Nov. 9, 2021 11:30 UTC PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter 2021. Third Quarter 2021 Highlights (compared to the same period last year) Revenue grew 37% to €214.5 million driven by strong sales in both segments; Net profit totaled €18.6 million and diluted EPS were €0.07, and both were tempered primarily by a discretionary, out-of-cycle bonus awarded to employees for their remarkable efforts over the last 18 months; Adjusted net profit increased 39% to €26.4 million; and adjusted diluted EPS were €0.10 Adjusted EBITDA grew 33% to €51.4 million; adjusted EBITDA margin was 24%; Backlog increased to €834 million; and, Based on year-to-date financial results and the visibility from backlog, the Company is increasing its revenue guidance and raising the bottom end of its ranges for adjusted diluted EPS and adjusted EBITDA. Third quarter revenue increased 37% to €214.5 million compared to the same period last year driven by strong sales in both segments. Gross profit increased 34% to €63.3 million, but gross profit margin of 29.5% was tempered primarily by higher sales in the Engineering Segment which has a lower margin than the Biopharmaceutical and Diagnostics Solutions Segment. In the third quarter, the Company awarded a discretionary bonus of €6.7 million to all staff to recognize their efforts over the past 18 months. The bonus was assumed in the Company’s 2021 guidance provided in the second quarter of 2021. The bonus adversely impacted operating profit, net profit, and diluted earnings per share (on a GAAP basis). In the third quarter, adjusted operating profit margin increased 80 basis points to 17%, adjusted net profit increased 39% to €26.4 million, and adjusted diluted EPS were €0.10. As expected, approximately 16% of third quarter 2021 revenue was attributable to Covid-19. In the third quarter, high value solutions accounted for approximately 23% of consolidated revenue which was primarily due the rapid increase in revenue. This compares to 24% in the prior-year period. Based on the current backlog, the Company expects a higher revenue contribution from high value solutions in the fourth quarter of 2021 in terms of overall dollar amounts. Franco Moro, Chief Executive Officer, stated, “We maintained strong momentum in the third quarter, driven by robust sales, a solid order pipeline and continued progress on our investments, innovation, and capacity expansion plans. Our Engineering Segment delivered better-than-expected results amid rising client demand, and we are pleased to increase our full year revenue guidance and raise the bottom end of the ranges for adjusted diluted EPS and adjusted EBITDA.” Moro continued, “Looking ahead, we remain squarely focused on delivering an integrated end-to-end product portfolio, supported by our scientific and analytical processes and services, to meet the rising needs of customers across the entire drug life cycle – from pre-clinical development stages to commercialization. We will continue to invest in the business to deliver sustainable, organic growth to drive long-term shareholder value.” Biopharmaceutical and Diagnostic Solutions Segment (BDS) The Biopharmaceutical and Diagnostic Solutions Segment delivers a broad range of proprietary products, processes, and services for the containment and delivery of pharmaceutical and biotechnology drugs, reagents, and diagnostic consumables. For the third quarter, BDS Segment revenue grew 31% to €172.8 million (third party sales) compared to the same period last year. Revenue growth was driven by a 32% increase from other containment and delivery solutions and a 29% increase in high value solutions which includes the Company’s proprietary EZ-Fill® syringes, vials, and cartridges. The segment continues to benefit from the favorable tailwind of Covid-19, and the Company’s leading position in the vaccine space. In the third quarter, high value solutions accounted for 28% of BDS Segment revenue, compared to 28.5% in the prior-year period. As a result of the high level of visibility from its current backlog, the Company expects a higher revenue contribution from its high value solutions in the fourth quarter of 2021. For the third quarter of 2021, gross profit margin of 31.2% was tempered by product mix. The segment’s operating profit margin of 18.1% was impacted primarily by the out-of-cycle, discretionary bonus awarded to all staff during the third quarter of 2021. For the third quarter, adjusted operating profit margin for this segment was 21.3% compared to 21.2% in the prior year. Engineering Segment The Engineering Segment develops and manufactures equipment and technology for assembly, visual inspection, packaging, serialization, glass conversion, as well as comprehensive after-sales support to provide end-to-end solutions to the pharmaceutical, biotechnology and diagnostic manufacturing processes. For the third quarter, Engineering Segment revenue increased by 67% to €41.8 million (third party sales) compared to the same period last year, driven by strong sales in its glass conversion and visual inspection machines that helped bolster this segment’s margins in the quarter. For the third quarter, the segment’s gross profit margin increased to 15.4% compared to 11.9% last year. The segment’s operating profit margin grew to 7.1% and includes the unfavorable impact from the out-of-cycle, discretionary bonus. For the third quarter, adjusted operating profit margin for this segment was 9.0% compared to 0.6% for the same period last year. Liquidity and Balance Sheet The Company believes that it has adequate cash available to appropriately address its current liquidity needs. During the third quarter, the Company completed its initial public offering, and raised total primary net proceeds, including the overallotment, of approximately €380 million. As a result, the Company had a positive net financial position of €153.9 million and cash and cash equivalents totaled €428 million as of September 30, 2021. For the third quarter, net cash generated from operating activities was €17.9 million which was adversely impacted by income tax payments of approximately €13.7 million and increased working capital needs to sustain growth. Cash paid for capital expenditures totaled €28.6 million during the quarter in support of the Company’s long-term strategic expansion plans. This resulted in a negative Free Cash Flow of €9.9 million for the third quarter of 2021. Capital expenditures for fiscal 2021 are now expected to be lower than previously forecasted as some spending is expected to shift into fiscal 2022. Despite this shift, the Company’s investment plans remain on track. Subsequent Events Subsequent to September 30, 2021, the Company paid approximately €7.0 million to purchase the remaining 35% minority interest in Denmark-based SVM Automatik A/S which specializes in assembly, packaging machines, and serialization solutions to meet the needs of the bio-pharmaceutical and contract manufacturing industries. Additionally, the Company sold its remaining minority holdings in Swissfillon, a provider of fill and finish services to the pharmaceutical and contract manufacturing industries, for a net profit of approximately €12.3 million, or €0.05 of diluted earnings per share which will be recognized in the fourth quarter. This non-recurring gain will be excluded from the Company’s 2021 guidance for adjusted diluted earnings per share. The Company intends to reinvest the net proceeds into the business to support its long-term strategic growth platform. Full Year 2021 Guidance Based on the Company’s year-to-date financial results and the high level of visibility from backlog, the Company is increasing its revenue guidance and raising the bottom end of its ranges for adjusted diluted EPS and adjusted EBITDA for 2021. The Company now expects: Revenue in the range of €825 million to €835 million; Adjusted diluted EPS in the range of €0.45 to €0.47 (assuming weighted average shares outstanding of approximately 252.7 million); and Adjusted EBITDA in the range of €214 million to €217 million. The Company intends to provide 2022 guidance when it issues year-end results in March 2022. Conference Call and Webcast The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 CET) on November 9, 2021. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, please visit the “Financial Results” page, under the Financial Information tab of the Company's Investor Relations section of its website. To participate on the call please dial: United States: 855 979 6654 United Kingdom: 0800 640 6441 Canada: 833 294 2546 Italy: 800 684 570 Internaional: +44 20 3936 2999 Access Code: 659819 Preregistration: Listeners are encouraged to preregister for the call via the following link: , whereupon you will be provided with a unique dial-in number and access code. For Participants that do not preregister: A live broadcast of the conference call will also be available online at the following link: (access code 659819). Replay: An online archive of the broadcast will be available at the website shortly after the live call and will be available through Tuesday 23 November 2021. The recording will be accessible via the following link: (access code 889042). About Stevanato Group Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. For more information, please visit Forward-Looking Statements This press release contains certain forward-looking statements which include, or may include, words such as "raising", "believe", "potential", "increased", "future", "remain", "growing", "expect", "foreseeable", "expected", "to be", "includes", "estimated", "assumes", "would provide", and other similar terminology. Forward-looking statements contained in this prospectus include, but are not limited to, statements about: our future financial performance, including our revenue, operating expenses, and our ability to maintain profitability and operational and commercial capabilities; our expectations regarding the development of our industry and the competitive environment in which we operate; and our goals, strategies, and investment plans. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements : (i) our product offerings are highly complex, and, if our products do not satisfy applicable quality criteria, specifications and performance standards, we could experience lost sales, delayed or reduced market acceptance of our products, increased costs and damage to our reputation; (ii) we must develop new products and enhance existing products, adapt to significant technological and innovative changes and respond to introductions of new products by competitors to remain competitive; (iii) our backlog might not accurately predict our future revenue, and we might not realize all or any part of the anticipated revenue reflected in our backlog; (iv) if we fail to maintain and enhance our brand and reputation, our business, results of operations and prospects may be materially and adversely affected; (v) we are highly dependent on our management and employees. Competition for our employees is intense, and we may not be able to attract and retain the highly skilled employees that we need to support our business and our intended future growth; (vi) our business, financial condition and results of operations depend upon maintaining our relationships with suppliers and service providers; (vii) our business, financial condition and results of operations depend upon the availability and price of high-quality materials and energy supply and our ability to contain production costs; (viii) significant interruptions in our operations could harm our business, financial condition and results of operations; (ix) our manufacturing facilities are subject to operating hazards which may lead to production curtailments or shutdowns and have an adverse effect on our business, results of operations, financial condition or cash flows; (x) our business may be harmed if our customers discontinue or spend less on research, development, production or other scientific endeavors; and (xi) we may face significant competition in implementing our strategies for revenue growth in light of actions taken by our competitors. This list is not exhaustive. These forward-looking statements speak only as at their dates. The Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible to predict all of these factors. Further, the Company cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statements. This press release also contains certain estimates regarding the Company's future prospects and performance, including, but not limited to, future revenues and earnings per share, capital deployment. All such statements and projections are based upon current expectations of the Company and involve a number of business risks and uncertainties. The Company disclaimers any current intention to update such guidance, except as required by law. For a description of certain additional factors that could cause the Company's future results to differ from those expressed in any such forward-looking statements, see Part II, Item 1A. entitled "Risk Factors" in the Company's Quarterly Report on Form 6-K for the quarterly period ended June 30, 2021 and "Risk Factors" in our registration statement on Form F-1, dated July 16, 2021 and which was filed with the U.S. Securities and Exchange Commission in accordance with Rule 424(b) of the Securities Act of 1933, as amended, on July 16, 2021. Consolidated Income Statement (Amounts in € millions, except per share data) (Unaudited) For the three months For the nine months ended September 30, ended September 30, 2021 % 2020 % 2021 % 2020 % Revenue 214.5 100.0% 157.1 100.0% 611.3 100.0% 455.3 100.0% Cost of sales 151.3 70.5% 109.8 69.9% 419.0 68.5% 319.7 70.2% Gross Profit 63.3 29.5% 47.2 30.1% 192.4 31.5% 135.6 29.8% Other operating Income 1.7 0.8% 0.6 0.4% 7.2 1.2% 2.7 0.6% Selling and Marketing Expenses 4.7 2.2% 4.1 2.6% 16.0 2.6% 15.4 3.4% Research and Development Expenses 7.4 3.4% 4.7 3.0% 20.1 3.3% 12.5 2.7% General and Administrative Expenses 24.7 11.5% 16.3 10.4% 44.7 7.3% 45.1 9.9% Operating Profit 28.2 13.2% 22.7 14.4% 118.8 19.4% 65.2 14.3% Finance Income 2.1 1.0% 2.4 1.5% 6.4 1.0% 11.9 2.6% Finance Expense 8.0 3.7% 3.6 2.3% 13.7 2.2% 17.2 3.8% Share of Profit of an Associate 0.2 0.1% 0.2 0.1% 0.5 0.1% 0.4 0.1% Profit Before Tax 22.4 10.4% 21.7 13.8% 112.0 18.3% 60.3 13.2% Income Taxes 3.8 1.8% 5.1 3.2% 22.3 3.7% 15.7 3.5% Net Profit 18.6 8.7% 16.6 10.6% 89.7 14.7% 44.6 9.8% Earnings per share Basic earnings per common share 0.07 0.07 0.36 0.19 Diluted earnings per common share 0.07 0.07 0.36 0.19 Average common shares outstanding 264.5 240.5 248.7 240.5 Average shares assuming dilution 264.5 240.5 248.7 240.5 Reported Segment Information (Amounts in € million, except per share data) (Unaudited) As at and for the three months ended September 30, 2021 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 172.8 41.8 - 214.5 Inter-Segment 0.3 17.7 (18.0) - Revenue 173.1 59.5 (18.0) 214.5 Gross Profit 53.9 9.2 0.2 63.3 Gross Profit Margin 31.2% 15.4% 29.5% Operating Profit 31.3 4.2 (7.3) 28.2 Operating Profit Margin 18.1% 7.1% 13.2% As at and for the three months ended September 30, 2020 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 132.1 25.0 - 157.1 Inter-Segment 0.1 10.3 (10.4) - Revenue 132.2 35.3 (10.4) 157.1 Gross Profit 43.7 4.2 (0.7) 47.2 Gross Profit Margin 33.1% 11.9% 30.1% Operating Profit 25.3 0.2 (2.8) 22.7 Operating Profit Margin 19.1% 0.6% 14.4% As at and for the nine months ended September 30, 2021 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 508.2 103.2 - 611.3 Inter-Segment 0.8 39.3 (40.1) - Revenue 509.0 142.4 (40.1) 611.3 Gross Profit 168.8 25.6 (2.0) 192.4 Gross Profit Margin 33.2% 18.0% 31.5% Operating Profit 111.2 12.0 (4.4) 118.8 Operating Profit Margin 21.8% 8.4% 19.4% Reported Segment Information (Continued) (Amounts in € million, except per share data) (Unaudited) As at and for the nine months ended September 30, 2020 Biopharmaceutical and Diagnostic Solutions Engineering Adjustments, eliminations and unallocated items Consolidated External Customers 394.9 60.4 - 455.3 Inter-Segment 0.5 38.1 (38.7) - Revenue 395.4 98.5 (38.7) 455.3 Gross Profit 123.6 14.9 (2.9) 135.6 Gross Profit Margin 31.3% 15.1% 29.8% Operating Profit 71.6 3.4 (9.8) 65.2 Operating Profit Margin 18.1% 3.4% 14.3% Consolidated Statement of Financial Position (Unaudited) (Amounts in € millions) (Amounts in € millions) As of September 30, 2021 As of December 31, 2021 - Intangible assets 79.2 81.1 - Right of use assets 23.3 25.4 - Property, plant and equipment 353.5 313.7 - Other non-current financial assets 5.0 8.1 - Deferred tax assets 52.2 45.6 Non-current assets 513.2 473.9 - Inventories 148.3 139.4 - Contract Assets 64.5 39.4 - Trade receivables 154.7 127.8 - Trade payables (130.4) (118.7) - Advances from customers (30.2) (48.4) - Contract Liabilities (13.9) (5.0) Trade working capital 193.0 134.5 - Other liabilities (net of receivables) (38.0) (33.8) Net working capital 155.0 100.7 - Deferred tax liabilities (13.9) (11.6) - Employees benefits (11.0) (29.7) - Provisions (4.0) (4.4) - Other non-current liabilities (1.8) (1.8) Total non-current liabilities and provisions (30.7) (47.5) Capital employed 637.6 527.0 Net debt 153.9 (216.9) Equity (791.5) (310.1) Total equity and net debt (637.6) (527.0) Cash Flow (Unaudited) (Amounts in € millions) For the three months ended September 30, For the nine months ended September 30, 2021 2020 2021 2020 Cash flow from operating activities 17.9 50.1 77.9 94.8 Cash flow used in investing activities (28.6) (20.8) (75.3) (64.3) Cash flow from/ (used in) financing activities 337.1 (20.7) 307.3 (0.2) Net change in cash and cash equivalents 326.4 8.6 309.8 30.2 Non-GAAP Financial Information This press release contains non-GAAP measures. Please refer to the tables included in this press release for a reconciliation of non-GAAP measures. Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, CAPEX, Adjusted Diluted EPS, Net Debt, and Free Cash Flow. We believe that these non-GAAP financial measures provide useful and relevant information regarding our performance and improve our ability to assess our financial condition. While similar measures are widely used in the industry in which we operate, the financial measures we use may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS. Reconciliation of Non-GAAP Measures (Unaudited) Reconciliation of Revenue to Constant Currency Revenue (Unaudited) (Amounts in € millions) Three months ended September 30, 2021 Biopharmaceutical and Diagnostic Solutions Engineering Reported Revenue (IFRS GAAP) 172.8 41.8 Effect of changes in currency translation rates (1.7) (0.1) Organic Revenue (Non-IFRS GAAP) 171.1 41.7 Nine months ended September 30, 2021 Biopharmaceutical and Diagnostic Solutions Engineering Reported Revenue (IFRS GAAP) 508.2 103.2 Effect of changes in currency translation rates 8.1 (0.2) Organic Revenue (Non-IFRS GAAP) 516.3 103.0 Reconciliation of EBITDA (Unaudited) (Amounts in € millions) For the three months ended September, 30 Change For the nine months ended September 30, Change 2021 2020 % 2021 2020 % Net Profit 18.6 16.6 12.1% 89.7 44.6 101.2% Income Taxes 3.8 5.1 (25.7%) 22.3 15.7 42.0% Finance Income (2.1) (2.4) (14.4%) (6.4) (11.9) (46.4%) Finance Expenses 8.0 3.6 126.2% 13.7 17.2 (20.4%) Share of Profit of an Associate (0.2) (0.2) (4.5%) (0.5) (0.4) 47.4% Operating Profit 28.2 22.7 24.4% 118.8 65.2 82.1% Depreciation and Amortization 14.9 13.2 13.1% 41.3 38.9 6.2% EBITDA 43.2 35.9 20.3% 160.1 104.1 53.8% Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Net Income, Taxes, Net Profit, and Diluted EPS (Unaudited) (Amounts in € millions, except per share data) Three months ended September 30, 2021 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 43.2 28.2 3.8 18.6 0.07 Adjusting items: Restructuring and related charges (1) 0.2 0.2 0.1 0.1 0.00 Incentive Plans Settlement (2) 0 0 0 0 - IPO costs (3) 0.7 0.7 0.2 0.5 0.00 Out-of-cycle bonus to personnel (4) 6.7 6.7 1.8 4.9 0.02 Foreign exchange loss for derivates on IPO proceeds (5) 0 0 1.0 3.3 0.01 Start-up costs U.S. plant (6) 0.6 0.6 0.2 0.5 0.00 Patent Box (7) 0 0 1.6 (1.6) (0.01) Adjusted 51.4 36.5 8.6 26.4 0.10 Adjusted Margin 24.0% 17.0% Nine months ended September 30, 2021 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 160.1 118.8 22.3 89.7 0.36 Adjusting items: Restructuring and related charges (1) 1.2 1.2 0.3 0.9 0.00 Incentive Plans Settlement (2) (9.9) (9.9) (4.8) (5.1) (0.02) IPO costs (3) 0.7 0.7 0.2 0.5 0.00 Out-of-cycle bonus to personnel (4) 6.7 6.7 1.8 4.9 0.02 Foreign exchange loss for derivates on IPO proceeds (5) - - 1.0 3.3 0.01 Start-up costs U.S. plant (6) 0.6 0.6 0.2 0.5 0.00 Patent Box (7) - - 7.1 (7.1) (0.03) Adjusted 159.4 118.1 28.2 87.5 0.35 Adjusted Margin 26.1% 19.3% Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Net Income, Taxes, Net Profit, and Diluted EPS (Unaudited) (Continued) (Amounts in € millions, except per share data) Three months ended September 30, 2020 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 35.9 22.7 5.1 16.6 0.07 Adjusting items: Litigation Costs (8) 2.7 2.7 0.8 2.4 0.01 Adjusted 38.6 25.4 5.9 19.0 0.08 Adjusted Margin 24.6% 16.2% Nine months ended September 30, 2020 EBITDA Operating Profit Income Taxes Net Profit Diluted EPS Reported 104.1 65.2 15.7 44.6 0.19 Adjusting items: Litigation Costs (8) 2.7 2.7 0.8 2.4 0.01 Adjusted 106.8 67.9 16.5 46.9 0.20 Adjusted Margin 23.5% 14.9% (1) During the three and the nine months ended September 30, 2021, the Group recorded €0.2 million and €1.2 million respectively in restructuring and related charges for the consolidation of Balda plants in the U.S. (2) During the nine months ended September 30, 2021, the Group recorded €9.9 million, within general and administrative expenses, as accrual reversal related to the early termination of incentive plans aimed at a limited number of key managers. The three months ended September 30, 2021, are not affected by this non-recurring item. (3) During the three and the nine months ended September 30, 2021, the Group recorded €0.7 million, within general and administrative expenses, relating to the listing of Stevanato Group S.p.a. ordinary shares on the NYSE. (4) During the three and the nine months ended September 30, 2021, the Group granted a €6.7 million discretionary, out-of-cycle, discretionary bonus to employees. (5) During the three and the nine months ended September 30, 2021, the Group recorded €4.3 million, as foreign exchange loss for derivates on IPO proceeds. (6) During the first three quarters of 2021, the Group recorded €0.6 million start-up costs to further the construction of the new plant in Fisher, Indiana, United States. (7) During the first three quarters of 2021, the Group reached an agreement with the Italian Tax Agency regarding the so-called “Patent box regime”, resulting in a retroactive €7.1 million tax saving for the financial years 2016-2020. The tax benefit was accounted for as €5.5 million for the three months ended March 31, 2021, based on our estimates. We accounted for an additional accrual of €1.6 million for the three months ended September 30, 2021, due to the timing of the ruling by the Italian Tax Agency. (8) During the first three quarters of 2020, the Group recorded €2.7 million related to litigation costs arising from a lawsuit brought by Clere BSD GmbH in connection with the payment of certain transfer fees for the acquisition of a patent by Balda AG, one of the Group’s subsidiaries. Reconciliation of Segment Operating Profit (Unaudited) (Amounts in € millions) Biopharmaceutical and Diagnostic Solutions Engineering Three months ended September 30, 2021 Operating Profit Operating Profit Reported 31.3 4.2 Adjusting items: Restructuring and related charges (9) 0.2 - Out-of-cycle bonus to personnel (10) 4.8 1.1 Start-up costs U.S. plant (11) 0.5 - Adjusted 36.8 5.4 Adjusted Margin 21.3% 9.0% Biopharmaceutical and Diagnostic Solutions Engineering Nine months ended September 30, 2021 Operating Profit Operating Profit Reported 111.2 12.0 Adjusting items: Restructuring and related charges (9) 1.2 - Out-of-cycle bonus to personnel (10) 4.8 1.1 Start-up costs U.S. plant (11) 0.5 - Adjusted 117.7 13.2 Adjusted Margin 23.1% 9.2% Biopharmaceutical and Diagnostic Solutions Engineering Three months ended September 30, 2020 Operating Profit Operating Profit Reported 25.3 0.2 Adjusting items: Litigation Costs (12) 2.7 - Adjusted 28.0 0.2 Adjusted Margin 21.2% 0.6% Biopharmaceutical and Diagnostic Solutions Engineering Nine months ended September 30, 2020 Operating Profit Operating Profit Reported 71.6 3.4 Adjusting items: Litigation Costs (12) 2.7 - Adjusted 74.3 3.4 Adjusted Margin 18.8% 3.4% (9) During the three and the nine months ended September 30, 2021, the Group recorded €0.2 million and €1.2 million respectively in restructuring and related charges for the consolidation of Balda plants in the U.S. These costs impacted only Biopharmaceutical and Diagnostic Solutions Segment. (10) During the three and the nine months ended September 30, 2021, the Group granted a €6.7 million a discretionary, out-of-cycle discretionary bonus to employees of which €4.8 million impacted Biopharmaceutical and Diagnostic Solutions Segment and €1.1 million impacted Engineering Segment. (11) During the first three quarters of 2021, the Group recorded €0.6 million start-up costs to further the construction of the new plant in Fisher, Indiana, United States of which €0.5 impacted Biopharmaceutical and Diagnostic Solutions Segment. (12) During the first three quarters of 2020, the Group recorded €2.7 million related to litigation costs arising from a lawsuit brought by Clere BSD GmbH in connection with the payment of certain transfer fees for the acquisition of a patent by Balda AG, one of the Group’s subsidiaries. Free Cash Flow (Unaudited) (Amounts in € millions) For the three months ended September 30, For the nine months ended September 30, 2021 2020 2021 2020 Cash Flow from Operating Activities 17.9 50.1 77.9 94.8 Interest paid 0.9 1.7 3.1 4.2 Interest received (0.1) (0.1) (0.5) (0.5) Purchase of property, plant, and equipment (27.3) (19.4) (71.4) (60.8) Purchase of intangible assets (1.3) (1.4) (3.4) (3.5) Free Cash Flow (9.9) 30.9 5.8 34.2 Reconciliation of 2021 Guidance for Adjusted EBITDA, Adjusted Operating Profit, Adjusted Net Profit and Adjusted Diluted EPS (Unaudited) (Amounts in € millions, except per share data) EBITDA Operating Profit Net Profit Diluted EPS Reported 214.2-217.2 157.2-160.2 127.8-132.9 0.51-0.53 Adjusting items Restructuring and Related charges 1.2 1.2 0.9 0.00 Incentive plans settlement (9.9) (9.9) (5.1) (0.02) Tax incentive - Patent Box (7.1) (0.03) Out-of-cycle bonus to personnel 6.7 6.7 4.9 0.02 IPO costs 0.7 0.7 0.5 0.00 Foreign exchange loss for derivates on IPO proceeds 3.3 0.01 Start-up costs U.S. plant 1.1 1.1 0.8 0.00 Gain from sales of minority (Swissfillon) (12.3) (0.05) Adjusted 214 - 217 157-160 113.7-118.8 0.45 - 0.47